Ultragenyx Pharmaceutical (RARE) Goodwill & Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Goodwill & Intangibles for 10 consecutive years, with $218.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles fell 1.33% year-over-year to $218.0 million; the TTM figure through Mar 2026 stood at $218.0 million (down 1.33% YoY), while the FY2025 annual figure was $220.0 million, down 0.9% from the prior year.
• Goodwill & Intangibles eased to $218.0 million in Q1 2026 per RARE's latest filing, from $220.0 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $222.0 million in Q4 2024 and bottomed at $201.7 million in Q3 2023.
• Historically, Goodwill & Intangibles has averaged $211.1 million across 5 years, with a median of $209.5 million in 2024.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles advanced 16.73% — and 2026, when it retreated 1.33%.
• Ultragenyx Pharmaceutical's Goodwill & Intangibles stood at $204.5 million in 2022, then advanced by 6.68% to $218.2 million in 2023, then increased by 1.75% to $222.0 million in 2024, then fell by 0.9% to $220.0 million in 2025, then fell by 0.91% to $218.0 million in 2026.
• Business Quant data shows RARE's Goodwill & Intangibles at $218.0 million in Q1 2026, $220.0 million in Q4 2025, and $217.3 million in Q3 2025.